Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


Articles published in Mol Carcinog

Retrieve available abstracts of 46 articles:
HTML format



Single Articles


    July 2024
  1. YANG Q, Sun K, Gao T, Gao Y, et al
    SIRT1 silencing promotes EMT and Crizotinib resistance by regulating autophagy through AMPK/mTOR/S6K signaling pathway in EML4-ALK L1196M and EML4-ALK G1202R mutant non-small cell lung cancer cells.
    Mol Carcinog. 2024 Jul 30. doi: 10.1002/mc.23799.
    PubMed     Abstract available


  2. LAI Q, Wan Y, Zhang Y, Huang Y, et al
    Hypomethylation-associated LINC00987 downregulation induced lung adenocarcinoma progression by inhibiting the phosphorylation-mediated degradation of SND1.
    Mol Carcinog. 2024;63:1260-1274.
    PubMed     Abstract available


    June 2024
  3. DENG Z, Dou L, Luo Z, Liu R, et al
    AKAP95 regulates ubiquitination and degradation of cyclin Ds/Es, influencing the G1/S transition of lung cancer cells.
    Mol Carcinog. 2024 Jun 24. doi: 10.1002/mc.23781.
    PubMed     Abstract available


  4. LIANG X, Xu J, Jiang Y, Yan Y, et al
    Concomitant genomic features stratify prognosis to patients with advanced EGFR mutant lung cancer.
    Mol Carcinog. 2024 Jun 11. doi: 10.1002/mc.23750.
    PubMed     Abstract available


    May 2024
  5. CHEN C, Tang D, Xu S, Xiang L, et al
    The promotion of non-small cell lung cancer progression by collagen and calcium binding EGF domain 1 is mediated through the regulation of ERK/JNK/P38 phosphorylation by reactive oxygen species.
    Mol Carcinog. 2024 May 10. doi: 10.1002/mc.23736.
    PubMed     Abstract available


  6. DU X, Cheng C, Yang Y, Fan B, et al
    NSUN2 promotes lung adenocarcinoma progression through stabilizing PIK3R2 mRNA in an m(5)C-dependent manner.
    Mol Carcinog. 2024;63:962-976.
    PubMed     Abstract available


  7. YANG Y, Tian Z, He L, Meng H, et al
    RhoGDIbeta inhibition via miR-200c/AUF1/SOX2/miR-137 axis contributed to lncRNA MEG3 downregulation-mediated malignant transformation of human bronchial epithelial cells.
    Mol Carcinog. 2024;63:977-990.
    PubMed     Abstract available


    February 2024
  8. FURUSAWA T, Cavero R, Liu Y, Li H, et al
    Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer.
    Mol Carcinog. 2024 Feb 27. doi: 10.1002/mc.23705.
    PubMed     Abstract available


  9. LI Q, Li J, Wang J, Wang J, et al
    PLEK2 mediates metastasis and invasion via alpha5-nAChR activation in nicotine-induced lung adenocarcinoma.
    Mol Carcinog. 2024;63:253-265.
    PubMed     Abstract available


  10. HU M, Cheng H, Yang Y, Xu L, et al
    Valproic acid increased the efficacy of EGFR TKIs on EGFR/TP53 co-mutated lung cancers and downregulated mutant-p53 levels.
    Mol Carcinog. 2024;63:275-285.
    PubMed     Abstract available


    January 2024
  11. LI J, Li Y, Sun X, Wei L, et al
    Silencing lncRNA-DARS-AS1 suppresses nonsmall cell lung cancer progression by stimulating miR-302a-3p to inhibit ACAT1 expression.
    Mol Carcinog. 2024 Jan 30. doi: 10.1002/mc.23686.
    PubMed     Abstract available


  12. ZHANG X, Zhao Y, Yiminniyaze R, Zhu N, et al
    CDK10 suppresses metastasis of lung adenocarcinoma through inhibition of the ETS2/c-Raf/p-MEK/p-ERK signaling loop.
    Mol Carcinog. 2024;63:61-74.
    PubMed     Abstract available


    December 2023
  13. HUA T, Zhang C, Fu Y, Qin N, et al
    Integrative analyses of N6-methyladenosine-associated single-nucleotide polymorphisms (m6A-SNPs) identify tumor suppressor gene AK9 in lung cancer.
    Mol Carcinog. 2023 Dec 5. doi: 10.1002/mc.23669.
    PubMed     Abstract available


  14. JIANG T, Li N, Xu H, Sun L, et al
    Identification of ATAD3A as a key regulator in non-small cell lung cancer by promoting STAT3-induced cell proliferation and tumor angiogenesis.
    Mol Carcinog. 2023 Dec 5. doi: 10.1002/mc.23667.
    PubMed     Abstract available


  15. ZHANG C, Sun Q, Zhao J, Jiang N, et al
    JSI-124 inhibits cell proliferation and tumor growth by inducing autophagy and apoptosis in murine malignant mesothelioma.
    Mol Carcinog. 2023;62:1888-1901.
    PubMed     Abstract available


    November 2023
  16. CHEN J, Kang G, Lei W, Li J, et al
    DUSP22 suppresses tumor progression by directly dephosphorylating AKT in non-small cell lung cancer.
    Mol Carcinog. 2023 Nov 8. doi: 10.1002/mc.23654.
    PubMed     Abstract available


    October 2023
  17. LONG T, Li J, Yin T, Liu K, et al
    A genetic variant in gene NDUFAF4 confers the risk of non-small cell lung cancer by perturbing hsa-miR-215 binding.
    Mol Carcinog. 2023 Oct 3. doi: 10.1002/mc.23642.
    PubMed     Abstract available


    August 2023
  18. QIAO R, Zhu Q, Di F, Liu C, et al
    Hypomethylation of DYRK4 in peripheral blood is associated with increased lung cancer risk.
    Mol Carcinog. 2023 Aug 2. doi: 10.1002/mc.23612.
    PubMed     Abstract available


    July 2023
  19. ZHANG B, Zhao B, Han S, Chen S, et al
    CNOT4 suppresses nonsmall cell lung cancer progression by promoting the degradation of PAF1.
    Mol Carcinog. 2023 Jul 26. doi: 10.1002/mc.23599.
    PubMed     Abstract available


  20. WANG B, Shen XY, Pan LY, Li Z, et al
    The HDAC2-MTA3 interaction induces nonsmall cell lung cancer cell migration and invasion by targeting c-Myc and cyclin D1.
    Mol Carcinog. 2023 Jul 4. doi: 10.1002/mc.23604.
    PubMed     Abstract available


  21. SHAMEEM M, Bagherpoor AJ, Nakhi A, Dosa P, et al
    Mitochondria-targeted metformin (mitomet) inhibits lung cancer in cellular models and in mice by enhancing the generation of reactive oxygen species.
    Mol Carcinog. 2023 Jul 4. doi: 10.1002/mc.23603.
    PubMed     Abstract available


    June 2023
  22. CHEN C, Xue N, Liu K, He Q, et al
    USP12 promotes nonsmall cell lung cancer progression through deubiquitinating and stabilizing RRM2.
    Mol Carcinog. 2023 Jun 21. doi: 10.1002/mc.23593.
    PubMed     Abstract available


  23. GE W, Gong Y, Li Y, Wu N, et al
    IL-17 induces non-small cell lung cancer metastasis via GCN5-dependent SOX4 acetylation enhancing MMP9 gene transcription and expression.
    Mol Carcinog. 2023 Jun 9. doi: 10.1002/mc.23585.
    PubMed     Abstract available


    May 2023
  24. FAN J, Hong T, Zhao X, Liang S, et al
    A two-stage genome-wide association study identified four potential early-onset nonsmall cell lung cancer risk loci based on 26,652 participants in Chinese population.
    Mol Carcinog. 2023 May 26. doi: 10.1002/mc.23561.
    PubMed     Abstract available


  25. PETER RM, Sarwar MS, Mostafa SZ, Wang Y, et al
    Histone deacetylase inhibitor belinostat regulates metabolic reprogramming in killing KRAS-mutant human lung cancer cells.
    Mol Carcinog. 2023 May 5. doi: 10.1002/mc.23551.
    PubMed     Abstract available


  26. GE P, Chen X, Liu J, Jing R, et al
    Hsa_circ_0088036 promotes nonsmall cell lung cancer progression by regulating miR-1343-3p/Bcl-3 axis through TGFbeta/Smad3/EMT signaling.
    Mol Carcinog. 2023 May 3. doi: 10.1002/mc.23547.
    PubMed     Abstract available


    April 2023
  27. YANG XR, Pi C, Zhang YC, Chen ZH, et al
    Heterogeneity in the immune microenvironment of bone metastasis in driver-positive non-small cell lung cancer.
    Mol Carcinog. 2023 Apr 17. doi: 10.1002/mc.23541.
    PubMed     Abstract available


  28. ADHIKARY G, Shrestha S, Naselsky W, Newland JJ, et al
    Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formation.
    Mol Carcinog. 2023;62:438-449.
    PubMed     Abstract available


    March 2023
  29. CHEN KJ, Huang JH, Shih JH, Gu DL, et al
    Somatic A-to-I RNA-edited RHOA isoform 2 specific-R176G mutation promotes tumor progression in lung adenocarcinoma.
    Mol Carcinog. 2023;62:348-359.
    PubMed     Abstract available


    January 2023
  30. CHEN D, Fan S, Wang J, Liang Y, et al
    Cip2a induces arginine biosynthesis and promotes tumor progression in non-small cell lung cancer.
    Mol Carcinog. 2023 Jan 27. doi: 10.1002/mc.23507.
    PubMed     Abstract available


    December 2022
  31. HOU J, Li W, Zhang S, Tan D, et al
    UHRF1 plays an oncogenic role in small cell lung cancer.
    Mol Carcinog. 2022 Dec 20. doi: 10.1002/mc.23493.
    PubMed     Abstract available


  32. ZHU Y, Chen B, Pan H, Sun L, et al
    PLIC11 drives lung cancer progression through regulating the YY1/PIWIL4 axis.
    Mol Carcinog. 2022 Dec 20. doi: 10.1002/mc.23496.
    PubMed     Abstract available


  33. ZHANG Z, Chen Q, Huang C, Rao D, et al
    Transcription factor Nrf2 binds to circRNAPIBF1 to regulate SOD2 in lung adenocarcinoma progression.
    Mol Carcinog. 2022;61:1161-1176.
    PubMed     Abstract available


    October 2022
  34. OHTAKI Y, Kawabata-Iwakawa R, Nobusawa S, Goto Y, et al
    Molecular and expressional characterization of tumor heterogeneity in pulmonary carcinosarcoma.
    Mol Carcinog. 2022;61:924-932.
    PubMed     Abstract available


  35. XIE J, Liao G, Feng Z, Liu B, et al
    ERO1L promotes the proliferation and metastasis of lung adenocarcinoma via the Wnt2/beta-catenin signaling pathway.
    Mol Carcinog. 2022;61:897-909.
    PubMed     Abstract available


    September 2022
  36. QIAO Z, Kong Y, Zhang Y, Qian L, et al
    Phosphoproteomics of extracellular vesicles integrated with multiomics analysis reveals novel kinase networks for lung cancer.
    Mol Carcinog. 2022 Sep 23. doi: 10.1002/mc.23462.
    PubMed     Abstract available


  37. QIAN L, Vallega KA, Yao W, Wang D, et al
    Therapeutic potential of the novel Bcl-2/Bcl-XL dual inhibitor, APG1252, alone or in combination against non-small cell lung cancer.
    Mol Carcinog. 2022 Sep 6. doi: 10.1002/mc.23458.
    PubMed     Abstract available


    August 2022
  38. GU J, Zhang X, Jiang G, Li Q, et al
    ARHGEF40 promotes non-small cell lung cancer proliferation and invasion via the AKT-Wnt axis by binding to RhoA.
    Mol Carcinog. 2022 Aug 24. doi: 10.1002/mc.23457.
    PubMed     Abstract available


  39. JIANG X, Qin N, Hua T, Wei X, et al
    Functional characterization and clinical significance of super-enhancers in lung adenocarcinoma.
    Mol Carcinog. 2022;61:776-786.
    PubMed     Abstract available


    June 2022
  40. NASELSKY W, Adhikary G, Shrestha S, Chen X, et al
    Transglutaminase 2 enhances hepatocyte growth factor signaling to drive the mesothelioma cancer cell phenotype.
    Mol Carcinog. 2022;61:537-548.
    PubMed     Abstract available


    May 2022
  41. CHEN AS, Liu H, Wu Y, Luo S, et al
    Genetic variants in DDO and PEX5L in peroxisome-related pathways predict non-small cell lung cancer survival.
    Mol Carcinog. 2022 May 3. doi: 10.1002/mc.23400.
    PubMed     Abstract available


    April 2022
  42. YANG P, Li X, Wen Q, Zhao X, et al
    Quercetin attenuates the proliferation of arsenic-related lung cancer cells via a caspase-dependent DNA damage signaling.
    Mol Carcinog. 2022 Apr 18. doi: 10.1002/mc.23408.
    PubMed     Abstract available


  43. KANG N, Qiu WJ, Wang B, Tang DF, et al
    Role of hemoglobin alpha and hemoglobin beta in non-small-cell lung cancer based on bioinformatics analysis.
    Mol Carcinog. 2022 Apr 8. doi: 10.1002/mc.23404.
    PubMed     Abstract available


    December 2021
  44. RIZWAN MN, Ma Y, Nenkov M, Jin L, et al
    Tumor-derived exosomes: Key players in non-small cell lung cancer metastasis and their implication for targeted therapy.
    Mol Carcinog. 2021 Dec 12. doi: 10.1002/mc.23378.
    PubMed     Abstract available


    October 2021
  45. XIAO M, Cui S, Zhang L, Yu T, et al
    Benzo[a]pyrene diol epoxide-induced transformed cells identify the significance of hsa_circ_0051488, a ERCC1-derived circular RNA in pulmonary squamous cell carcinoma.
    Mol Carcinog. 2021;60:684-701.
    PubMed     Abstract available


    August 2021
  46. HU W, Ma Y, Zhao C, Yin S, et al
    Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer.
    Mol Carcinog. 2021 Aug 19. doi: 10.1002/mc.23340.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.